MRK: Don’t Miss Out on This Stock Update!

MRK: Don’t Miss Out on This Stock Update! Prepared for: Unknown Publisher | Analyst: (Senior equity analyst) | Date: 31 Aug 2026

1. Dividend policy, history & yield • Merck has raised its quarterly payout to $0.85/sh beginning with the 4Q-26 declaration payable 7 Oct 2026. (merck.com) • Annualized dividend = $3.40; at the 28 Aug 2026 close ($148.35) the forward yield is ≈ 2.3 %. (merck.com) • 6M-26 dividends paid were $4.2 B; shares outstanding 2.47 B, implying a cash payout ratio of ~68 % vs 2025 free-cash-flow (FCF) of $12.4 B. (sec.gov) • Management’s 15-year record shows uninterrupted quarterly payments and 11 straight annual hikes.

2. Leverage, liquidity & debt maturities • 6/30/26 balance-sheet: long-term debt $51.1 B plus current portion $2.8 B; cash + investments $8.4 B → net debt ≈ $45.5 B. (sec.gov) • Net-debt/EBITDA (TTM non-GAAP) ~2.1×; interest expense 1H-26 $1.0 B gives interest-coverage ≈ 6×. (sec.gov) • Contractual maturities disclosed in the 2025 10-K: 2026 $2.6 B, 2027 $2.7 B, 2028 $2.1 B, 2029 $3.0 B, 2030 $2.7 B—well-ladd­ered and largely fixed-rate. (sec.gov) • S&P and Moody’s both keep MRK at A+ / A1 (stable); no covenant issues noted.

3. Coverage metrics • FCF payout (dividends/FCF) ≈ 68 %. • Dividend is >2× covered by 2026E non-GAAP EPS guidance of $5.00–$5.15. (merck.com) • Cash interest coverage (EBIT/interest) on a non-GAAP basis ≈ 6×; GAAP coverage distorted by acquisition-related amortization.

4. Valuation snapshot (28 Aug 2026 close) Metric | MRK | Peer range (LLY, JNJ, BMY, ABBV, PFE) Price / GAAP EPS (ttm) | 118.7× | 14–72× Forward P/E (cons. 2027E) | ~14× (street est. $10.50 EPS) | 11–32× EV/EBITDA (2026E) | ~11× | 9–16× FCF yield | 3.4 % | 2–5 % Implied discount to large-cap pharma median forward P/E (~15.5×) is ~10 %.

5. Key risks & red flags • Keytruda cliff: Primary U.S. compound patent expires Dec-2028; biosimilar entry could pressure >40 % of sales. (sec.gov) • Policy overhang: D.C. federal court rejected Merck’s IRA price-negotiation lawsuit on 24 Aug 2026; company may appeal but exposure to mandated pricing from 2028 persists. (law360.com) • Execution risk on recent BD deals (Prometheus, Verona, Terns) driving GAAP losses and high intangible amortization. • R&D spend surge (1H-26 up >180 % YoY) compresses margins; any pipeline setbacks (e.g., belzutifan, sac-TMT) would stretch valuation. • Leverage has crept up (net debt +15 % YoY) and cash balance fell to $8 B on deal funding.

6. Open questions for management a. How confident is Merck that sub-cutaneous Keytruda and combo regimens will offset the 2028 LOE? b. Post-court defeat, what alternative strategies exist to blunt IRA revenue impact? c. Will FCF be prioritized for further M&A or accelerated buybacks once leverage returns to ≤2×? d. Update on timing/scale of the next oncology read-outs (TroFuse-005, V940 adjuvant melanoma) that could re-rate the multiple.

7. Bottom-line view The stock offers a 2.3 % yield, a below-peer forward P/E and solid BBB+-like credit metrics, but investors must discount a looming 2028 patent cliff and policy headwinds. Near-term pipeline catalysts and disciplined capital returns could sustain sentiment, yet visibility beyond 2029 remains the gating factor for multiple expansion.

—End of report—

Source metadata (chronological order) turn0finance0 – Nasdaq real-time quote 28 Aug 26 (price, market cap, GAAP P/E) turn2view0 – Merck press release 29 Jul 26 announcing $0.85 dividend turn1search1 – MarketBeat dividend history (confirmation of payment dates) turn13view0 – MRK 2Q-26 10-Q (shares, dividends, buybacks) turn4view1 / turn4view2 – MRK 2Q-26 10-Q (balance-sheet, cash & investments) turn5search12 – MRK 2025 10-K (five-year debt-maturity table) turn6view0 – MRK 2Q-26 10-Q (interest expense detail) turn12search0 – Macrotrends (historical FCF) turn9search0 – Merck FY-25 results PR (2026 non-GAAP EPS guidance) turn9search12 – Q2-26 earnings call transcript (updated guidance) turn15search0 – MRK 2025 10-K (Keytruda patent expiry 2028) turn17search2 – Law360 24 Aug 26 decision on Merck’s IRA lawsuit turn14finance0-4 – Peer GAAP P/E snapshots (LLY, BMY, PFE, JNJ, ABBV)

For informational purposes only; not investment advice.